

(19) United States

(12) Patent Application Publication (10) Pub. No.: US 2021/0230283 A1 Dix et al.

Jul. 29, 2021 (43) **Pub. Date:**

(54) STABILIZED FORMULATIONS **CONTAINING ANTI-INTERLEUKIN-6** RECEPTOR (IL-6R) ANTIBODIES

(71) Applicant: Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US)

(72) Inventors: Daniel B. Dix, LaGrangeville, NY (US); Kenneth S. Graham, Pleasant Valley, NY (US); Douglas Kamen, Poughquag, NY (US); Scott M. Walsh,

Tarrytown, NY (US)

(21) Appl. No.: 17/225,887

(22) Filed: Apr. 8, 2021

Related U.S. Application Data

- (63) Continuation of application No. 16/100,020, filed on Aug. 9, 2018, which is a continuation of application No. 14/861,565, filed on Sep. 22, 2015, now Pat. No. 10,072,086, which is a continuation of application No. 12/986,223, filed on Jan. 7, 2011, now Pat. No. 9,173,880.
- (60) Provisional application No. 61/293,227, filed on Jan. 8, 2010.

Publication Classification

(51)	Int. Cl.	
. ,	C07K 16/28	(2006.01)
	A61K 9/00	(2006.01)
	A61K 31/485	(2006.01)
	A61K 47/18	(2006.01)
	A61K 47/26	(2006.01)
	C07K 16/24	(2006.01)
	A61J 1/06	(2006.01)
	A61K 39/395	(2006.01)
	A61K 47/22	(2006.01)

(52) U.S. Cl.

CPC C07K 16/2866 (2013.01); A61K 9/0019 (2013.01); A61K 31/485 (2013.01); A61K 47/183 (2013.01); A61K 47/26 (2013.01); A61K 2039/505 (2013.01); A61J 1/065 (2013.01); A61K 39/3955 (2013.01); A61K 47/22 (2013.01); C07K 2317/515 (2013.01); C07K 16/248 (2013.01)

(57)ABSTRACT

The present invention provides pharmaceutical formulations comprising a human antibody that specifically binds to human interleukin-6 receptor (hIL-6R). The formulations may contain, in addition to an anti-hIL-6R antibody, at least one amino acid, at least one sugar, and/or at least one non-ionic surfactant. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months.

Specification includes a Sequence Listing.